Rationale and Design for Shiga Microalbuminuria Reduction Trial
Status:
Unknown status
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial are to evaluate the reduction of urinary albumin excretion by an
angiotensin receptor blocker (ARB), valsartan, in comparison with a calcium channel blocker
(CCB), amlodipine, in Japanese hypertensive patients with type 2 diabetes mellitus and
microalbuminuria under strict blood pressure control, and to compare the additional effects
of an ARB or a CCB in combination with angiotensin-converting enzyme (ACE) inhibitor
treatment.